Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives

  title={Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives},
  author={M. Raps and F. Helmerhorst and K. Fleischer and S. Thomassen and F. Rosendaal and J. Rosing and B. Ballieux and H. van Vliet},
  journal={Journal of Thrombosis and Haemostasis},
  • M. Raps, F. Helmerhorst, +5 authors H. van Vliet
  • Published 2012
  • Medicine
  • Journal of Thrombosis and Haemostasis
  • Summary.  Background: It takes many years to obtain reliable values for the risk of venous thrombosis of hormonal contraceptive users from clinical data. Measurement of activated protein C (APC) resistance via thrombin generation is a validated test for determining the thrombogenicity of hormonal contraceptives. Sex hormone‐binding globulin (SHBG) might serve as a marker for the risk of venous thrombosis, and can be easily and rapidly measured in routine laboratories. 
    61 Citations
    Sex hormone-binding globulin and thrombin generation in women using hormonal contraception
    • 5
    • Highly Influenced
    Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
    • 11
    Oral Contraceptives and HRT Risk of Thrombosis
    • 16
    • Highly Influenced
    Endogenous sex hormones and risk of venous thromboembolism in young women
    • 4
    The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    • 22
    • PDF
    Epidemiology of hormonal contraceptives-related venous thromboembolism.
    • 47
    • PDF


    Estrogens, progestogens and thrombosis
    • 160
    Hormone therapies and venous thromboembolism: where are we now?
    • 54
    • PDF